Quoin制药公司报告罕见疾病治疗的积极临床数据
Investing.com — 目前市值为436万美元的专业制药公司Quoin Pharmaceuticals Ltd. (QNRX)今日宣布其正在进行的儿科奈瑟顿综合征研究取得了重大临床进展。其治疗药物QRX003在每日使用六周后显示能够维持几乎完全的皮肤愈合。这一进展尤为显著，因为患者不再需要额外的药物，如抗生素或抗组胺药，而这些在之前是必需的。根据 InvestingPro ...
Quoin announces additional data from Pediatric Netherton Syndrome study
Quoin Pharmaceuticals (QNRX) announces additional highly positive clinical data from its ongoing Investigator Pediatric Netherton Syndrome ...
Quoin申请皮肤病治疗药物QRX003专利
Investing.com — Quoin制药有限公司（纳斯达克股票代码：QNRX），一家市值610万美元的专业制药公司，已为QRX003提交美国专利申请，这是一种针对罕见皮肤疾病（包括Netherton综合征（NS））的外用治疗药物。该公司股票在过去一年下跌超过65%，目前正在进行四项针对NS的临床试验，其中三项在美国食品药品监督管理局（FDA）的开放性研究性新药（IND）申请下进行。根据 ...
Quoin Pharmaceuticals Files U.S. Patent Application for Novel Topical Formulations to Treat ...
Target Indications Also Include Peeling Skin Syndrome, SAM Syndrome, Palmoplantar Keratoderma and Severe Atopic ...
Nasdaq9 天
Quoin Pharmaceuticals Files Patent Application for QRX003 to Treat Netherton Syndrome and ...
Quoin Pharmaceuticals Ltd. has filed a U.S. patent application for new topical formulations aimed at treating several skin diseases, specifically Netherton Syndrome (NS) and Peeling Skin Syndrome.
ETF Daily News2 天
Contrasting Quoin Pharmaceuticals (NASDAQ:QNRX) and Phathom Pharmaceuticals (NASDAQ:PHAT)
Quoin Pharmaceuticals has higher earnings, but lower revenue than Phathom Pharmaceuticals. Phathom Pharmaceuticals is trading at a lower price-to-earnings ratio than Quoin Pharmaceuticals ...
Quoin files U.S. patent application for novel topical formulations
Quoin Pharmaceutical announced it has filed a U.S. patent application for novel topical formulations to treat a number of skin diseases, ...
Quoin Pharmaceuticals Files U.S. and International Patent Applications for Novel Topical ...
Target Indications Include Microcystic Lymphatic Malformations, Venous Malformations and AngiofibromasProprietary Invisicare ...